Barclays lifts Abbott PT on Exact Sciences acquisition

Barclays raises PT on medical device maker Abbott Laboratories ABT.N to $144 from $142

Reiterates rating at "overweight"

Barclays says it updated its model to reflect Abbott’s acquisition of Exact Sciences, lifting revenue estimates while factoring in near-term earnings dilution

The new price target represents a 41.4% upside to the stock's last close

Brokerage raises its 2026 sales forecast by about 6%, in line with management’s outlook, but cuts EPS estimates by roughly 4% due to deal-related dilution

Barclays expects the Exact acquisition to be modestly dilutive in 2026 and 2027, with earnings turning accretive longer term

Twenty-three of 31 brokerages rate the stock "buy" or higher, 8 "hold"; their median PT is $134.4, according to data compiled by LSEG

As of last close, stock down 18.7% YTD